Non-vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic prevention, are they safe in congenital heart disease? Results of a worldwide study

H. Yang, B. J. Bouma, K. Dimopoulos, P. Khairy, M. Ladouceur, K. Niwa, M. Greutmann, M. Schwerzmann, A. Egbe, G. Scognamiglio, W. Budts, G. Veldtman, A. R. Opotowsky, C. S. Broberg, L. Gumbiene, F. J. Meijboom, T. Rutz, M. C. Post, T. Moe, M. LipczyńskaS. F. Tsai, S. Chakrabarti, D. Tobler, W. Davidson, M. Morissens, A. van Dijk, J. Buber, J. Bouchardy, K. Skoglund, C. Christersson, T. Kronvall, T. C. Konings, R. Alonso-Gonzalez, A. Mizuno, G. Webb, M. Laukyte, G. T.J. Sieswerda, K. Shafer, J. Aboulhosn, B. J.M. Mulder

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Fingerprint

Dive into the research topics of 'Non-vitamin K antagonist oral anticoagulants (NOACs) for thromboembolic prevention, are they safe in congenital heart disease? Results of a worldwide study'. Together they form a unique fingerprint.

Medicine & Life Sciences